BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 38475882)

  • 21. Bioinformatics Analysis of KIF1A Expression and Gene Regulation Network in Ovarian Carcinoma.
    Lu X; Li G; Liu S; Wang H; Zhang Z; Chen B
    Int J Gen Med; 2021; 14():3707-3717. PubMed ID: 34321916
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Correlation Analysis of Prognostic Gene Expression, Tumor Microenvironment, and Tumor-Infiltrating Immune Cells in Ovarian Cancer.
    Li Q; Yang Z; Ling X; Ye J; Wu J; Wang Y; Yao C; Zheng J
    Dis Markers; 2023; 2023():9672158. PubMed ID: 37841886
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An integrated model of CDCA5 and FOXM1 expression combined with a residual disease that predicts prognosis in ovarian cancer patients.
    Zhang Q; Zhang R; Liu M; Wu H; Yang B
    Cell Mol Biol (Noisy-le-grand); 2023 Oct; 69(10):143-149. PubMed ID: 37953569
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Single-cell and transcriptomic analyses reveal the influence of diabetes on ovarian cancer.
    Zhao Z; Wang Q; Zhao F; Ma J; Sui X; Choe HC; Chen P; Gao X; Zhang L
    BMC Genomics; 2024 Jan; 25(1):1. PubMed ID: 38166541
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel biomarker, MRPS12 functions as a potential oncogene in ovarian cancer and is a promising prognostic candidate.
    Qiu X; Guo D; Du J; Bai Y; Wang F
    Medicine (Baltimore); 2021 Feb; 100(8):e24898. PubMed ID: 33663122
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of STEAP3-based molecular subtype and risk model in ovarian cancer.
    Zhao Z; Sun C; Hou J; Yu P; Wei Y; Bai R; Yang P
    J Ovarian Res; 2023 Jun; 16(1):126. PubMed ID: 37386521
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of key biomarkers associated with development and prognosis in patients with ovarian carcinoma: evidence from bioinformatic analysis.
    Shen J; Yu S; Sun X; Yin M; Fei J; Zhou J
    J Ovarian Res; 2019 Nov; 12(1):110. PubMed ID: 31729978
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comprehensive Analyses Identify APOBEC3A as a Genomic Instability-Associated Immune Prognostic Biomarker in Ovarian Cancer.
    Xu F; Liu T; Zhou Z; Zou C; Xu S
    Front Immunol; 2021; 12():749369. PubMed ID: 34745121
    [TBL] [Abstract][Full Text] [Related]  

  • 29. NLRP12 is a prognostic biomarker and correlated with immune infiltrates in epithelial ovarian cancer.
    Ma R; Tang Z; Wang J
    J Gene Med; 2024 Jan; 26(1):e3585. PubMed ID: 37926491
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification and validation of a seven m6A-related lncRNAs signature predicting prognosis of ovarian cancer.
    Song Y; Qu H
    BMC Cancer; 2022 Jun; 22(1):633. PubMed ID: 35676619
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune-Related Genes' Prognostic, Therapeutic and Diagnostic Value in Ovarian Cancer Immune-Related Gene Biomarker in Ovarian Cancer.
    Ding B; Yan W; Shen S; Meng D; Chen X; Wang S; Shen Y
    Cancer Control; 2023; 30():10732748231168756. PubMed ID: 37078136
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of Prognostic Biomarkers Among FAM83 Family Genes in Human Ovarian Cancer Through Bioinformatic Analysis and Experimental Verification.
    Lin S; Du J; Hao J; Luo X; Wu H; Zhang H; Zhao X; Xu L; Wang B
    Cancer Manag Res; 2021; 13():8611-8627. PubMed ID: 34815715
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prospective pathway signaling and prognostic values of MicroRNA-9 in ovarian cancer based on gene expression omnibus (GEO): a bioinformatics analysis.
    Zuo L; Li X; Tan Y; Zhu H; Xiao M
    J Ovarian Res; 2021 Feb; 14(1):29. PubMed ID: 33563317
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PAXIP1-AS1 is associated with immune infiltration and predicts poor prognosis in ovarian cancer.
    Chen B; Lu X; Zhou Q; Chen Q; Zhu S; Li G; Liu H
    PLoS One; 2023; 18(8):e0290031. PubMed ID: 37582104
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of PKP 2/3 as potential biomarkers of ovarian cancer based on bioinformatics and experiments.
    Gao L; Li X; Guo Q; Nie X; Hao Y; Liu Q; Liu J; Zhu L; Yan L; Lin B
    Cancer Cell Int; 2020; 20():509. PubMed ID: 33088217
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association between tumor mutation burden and immune infiltration in ovarian cancer.
    Fan S; Gao X; Qin Q; Li H; Yuan Z; Zhao S
    Int Immunopharmacol; 2020 Dec; 89(Pt A):107126. PubMed ID: 33189611
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comprehensive Analysis of
    Qi B; Liu S; Liu D; Yao H; Yan R
    Dis Markers; 2022; 2022():2687867. PubMed ID: 35140819
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bioinformatics analysis to screen the key prognostic genes in ovarian cancer.
    Li L; Cai S; Liu S; Feng H; Zhang J
    J Ovarian Res; 2017 Apr; 10(1):27. PubMed ID: 28407786
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Integrated analysis of prognostic immune-related genes in the tumor microenvironment of ovarian cancer.
    Wang J; Su X; Wang C; Xu M
    Ann Transl Med; 2022 Jan; 10(2):91. PubMed ID: 35282097
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of a necroptosis-related gene signature and the immune landscape in ovarian cancer.
    Nie S; Ni N; Chen N; Gong M; Feng E; Liu J; Liu Q
    J Ovarian Res; 2023 Apr; 16(1):82. PubMed ID: 37095524
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.